# Dinaciclib in Treating Patients With Stage IV Melanoma

> **NCT00937937** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 72 (actual)

## Conditions studied

- Acral Lentiginous Melanoma
- Cutaneous Nodular Melanoma
- Lentigo Maligna Melanoma
- Low-CSD Melanoma
- Mucosal Melanoma
- Recurrent Melanoma
- Stage IV Cutaneous Melanoma AJCC v6 and v7

## Interventions

- **DRUG:** Dinaciclib

## Key facts

- **NCT ID:** NCT00937937
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-07-01
- **Primary completion:** 2013-10-22
- **Final completion:** 2027-03-19
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00937937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00937937, "Dinaciclib in Treating Patients With Stage IV Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00937937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*